---
layout: default
title: Carboplatin
description: "Carboplatin çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚é«˜è­‰æ“šç­‰ç´š L2ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: é«˜è­‰æ“šç­‰ç´š (L1-L2)
nav_order: 40
evidence_level: L2
indication_count: 10
---

# Carboplatin

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L2</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Carboplatinï¼šå¾åŒ–ç™‚åŸºçŸ³åˆ°å¥³æ€§ä¹³è…ºç™Œçš„æ–°æ¢ç´¢

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Carboplatin å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Carboplatin æ˜¯é‰‘é¡æŠ—ç™Œè—¥ç‰©ï¼Œå·²å»£æ³›ç”¨æ–¼å¤šç¨®ç™Œç—‡æ²»ç™‚ã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**å¥³æ€§ä¹³è…ºç™Œ (female breast carcinoma)** æœ‰æ•ˆï¼Œ
ç›®å‰æœ‰è¶…é **50 å€‹è‡¨åºŠè©¦é©—**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | HER2 é™½æ€§æ—©æœŸä¹³ç™Œã€è½‰ç§»æ€§ä¹³ç™Œã€é»‘è‰²ç´ ç˜¤ã€éå°ç´°èƒè‚ºç™Œã€ä½•æ°é‡‘æ°æ·‹å·´ç˜¤ã€é ­é ¸éƒ¨é±—ç‹€ç´°èƒç™Œã€æ³Œå°¿é“ä¸Šçš®ç™Œç­‰ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | å¥³æ€§ä¹³è…ºç™Œã€primary non-gestational choriocarcinoma of ovaryã€hereditary breast ovarian cancer syndromeã€ovarian clear cell adenocarcinomaã€ovarian mucinous adenocarcinomaã€yolk sac tumorã€maligant granulosa cell tumor of ovaryã€ovarian endometrioid adenocarcinomaã€rectum mucinous adenocarcinomaã€colon mucinous adenocarcinoma |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.86% |
| è­‰æ“šç­‰ç´š | L2 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ï¼ˆç‚ºå¤šç¨®è¤‡æ–¹æ²»ç™‚çš„ä¸€éƒ¨åˆ†ï¼‰ |
| è¨±å¯è­‰æ•¸ | å¤šå¼µï¼ˆä½œç‚º Trastuzumabã€Pembrolizumab ç­‰è—¥ç‰©é©æ‡‰ç—‡çš„ä½µç”¨è—¥ç‰©ï¼‰ |
| å»ºè­°æ±ºç­– | Proceed with Guardrails |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. female breast carcinoma</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.86%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

Carboplatin æ˜¯ä¸€ç¨®é‰‘é¡æŠ—ç™Œè—¥ç‰©ï¼Œé€éèˆ‡ DNA å½¢æˆäº¤å‰é€£çµä¾†æŠ‘åˆ¶è…«ç˜¤ç´°èƒå¢æ®–ã€‚å…¶ä½œç”¨æ©Ÿè½‰åŒ…æ‹¬ï¼š

1. **DNA æå‚·æ©Ÿåˆ¶**ï¼šCarboplatin èˆ‡ DNA å½¢æˆé‰‘-DNA åŠ åˆç‰©ï¼Œå¹²æ“¾ DNA è¤‡è£½èˆ‡è½‰éŒ„
2. **ç´°èƒé€±æœŸé˜»æ»¯**ï¼šèª˜å°ç´°èƒé€±æœŸåœæ»¯ï¼Œä¿ƒé€²è…«ç˜¤ç´°èƒå‡‹äº¡
3. **å°ä¸‰é™°æ€§ä¹³è…ºç™Œçš„ç‰¹æ®Šç™‚æ•ˆ**ï¼šç ”ç©¶é¡¯ç¤º carboplatin å° BRCA çªè®Šç›¸é—œçš„ä¸‰é™°æ€§ä¹³è…ºç™Œå…·æœ‰è‰¯å¥½ç™‚æ•ˆ

### è‡¨åºŠè©¦é©—

| è©¦é©—ç·¨è™Ÿ | éšæ®µ | ç‹€æ…‹ | äººæ•¸ | ä¸»è¦ç™¼ç¾ |
|---------|------|------|------|---------|
| [NCT06027268](https://clinicaltrials.gov/study/NCT06027268) | Phase 2 | ACTIVE_NOT_RECRUITING | 36 | è©•ä¼° trilaciclibã€pembrolizumabã€gemcitabine å’Œ carboplatin åœ¨è½‰ç§»æ€§ä¸‰é™°æ€§ä¹³è…ºç™Œä¸­çš„ç™‚æ•ˆ |
| [NCT00047255](https://clinicaltrials.gov/study/NCT00047255) | Phase 3 | COMPLETED | 263 | æ¯”è¼ƒ docetaxel/trastuzumab èˆ‡ docetaxel/carboplatin/trastuzumab åœ¨ HER2 é™½æ€§è½‰ç§»æ€§ä¹³è…ºç™Œçš„ç™‚æ•ˆ |
| [NCT01881230](https://clinicaltrials.gov/study/NCT01881230) | Phase 2/3 | COMPLETED | 191 | è©•ä¼° nab-paclitaxel èˆ‡ gemcitabine æˆ– carboplatin åœ¨ä¸‰é™°æ€§è½‰ç§»æ€§ä¹³è…ºç™Œçš„ç™‚æ•ˆ |
| [NCT02413320](https://clinicaltrials.gov/study/NCT02413320) | Phase 2 | COMPLETED | 101 | è©•ä¼°å« carboplatin åŒ–ç™‚æ–¹æ¡ˆåœ¨ä¸‰é™°æ€§ä¹³è…ºç™Œæ–°è¼”åŠ©æ²»ç™‚ä¸­çš„ç—…ç†å®Œå…¨ç·©è§£ç‡ |
| [NCT01445418](https://clinicaltrials.gov/study/NCT01445418) | Phase 1 | COMPLETED | 103 | ç ”ç©¶ PARP æŠ‘åˆ¶åŠ‘ AZD2281 èˆ‡ carboplatin ä½µç”¨åœ¨ BRCA1/2 çªè®Šæ”œå¸¶è€…ä¹³è…ºç™Œä¸­çš„å®‰å…¨æ€§ |

### ç›¸é—œæ–‡ç»

Carboplatin åœ¨ä¹³è…ºç™Œæ²»ç™‚ä¸­çš„æ‡‰ç”¨å·²æœ‰å¤šé …ç ”ç©¶æ”¯æŒï¼Œå°¤å…¶åœ¨ä»¥ä¸‹é ˜åŸŸï¼š

1. **ä¸‰é™°æ€§ä¹³è…ºç™Œ (TNBC)**ï¼šå¤šé …è‡¨åºŠè©¦é©—é¡¯ç¤º carboplatin å¯æé«˜ TNBC çš„ç—…ç†å®Œå…¨ç·©è§£ç‡
2. **BRCA çªè®Šç›¸é—œä¹³è…ºç™Œ**ï¼šcarboplatin å° DNA ä¿®å¾©ç¼ºé™·çš„è…«ç˜¤ç´°èƒå…·æœ‰è¼ƒé«˜æ•æ„Ÿæ€§
3. **HER2 é™½æ€§ä¹³è…ºç™Œ**ï¼šèˆ‡ trastuzumab ä½µç”¨å·²è¢«è­‰å¯¦æœ‰æ•ˆ

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. rectum mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.28%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.28%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. colon mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.26%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.26%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. adult germ cell tumor</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.24%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.24%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. cervical mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.24%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.24%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. gallbladder mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.23%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.23%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. endometrial mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.20%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.20%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. endometrial mixed adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.20%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.20%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. villoglandular endometrial endometrioid adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.20%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.20%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. extrahepatic bile duct mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.18%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.18%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬027591è™Ÿ | æ›²æ–¯è‹¥å‡æ™¶æ³¨å°„åŠ‘150æ¯«å…‹ | å‡æ™¶æ³¨å°„åŠ‘ | èˆ‡ docetaxel åŠ carboplatin ä½µç”¨ä¹‹ HER2 é™½æ€§æ—©æœŸä¹³ç™Œè¼”åŠ©ç™‚æ³• |
| è¡›ç½²è—¥è¼¸å­—ç¬¬027591è™Ÿ | è³€ç™Œå¹³çš®ä¸‹æ³¨å°„åŠ‘ | çš®ä¸‹æ³¨å°„åŠ‘ | èˆ‡ docetaxel åŠ carboplatin ä½µç”¨ä¹‹ HER2 é™½æ€§æ—©æœŸä¹³ç™Œè¼”åŠ©ç™‚æ³• |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬028264è™Ÿ | å‰èˆ’é”è†œè¡£éŒ  | è†œè¡£éŒ  | èˆ‡ pemetrexed åŠ carboplatin ä½µç”¨ä¹‹è½‰ç§»æ€§éé±—ç‹€éå°ç´°èƒè‚ºç™Œç¬¬ä¸€ç·šæ²»ç™‚ |

## ç´°èƒæ¯’æ€§

| é …ç›® | å…§å®¹ |
|------|------|
| ç´°èƒæ¯’æ€§åˆ†é¡ | å‚³çµ±ç´°èƒæ¯’æ€§è—¥ç‰© |
| éª¨é«“æŠ‘åˆ¶é¢¨éšª | é«˜åº¦ï¼ˆè¡€å°æ¿æ¸›å°‘ç‚ºåŠ‘é‡é™åˆ¶æ¯’æ€§ï¼‰ |
| è‡´åæ€§åˆ†ç´š | ä¸­åº¦è‡³é«˜åº¦ |
| ç›£æ¸¬é …ç›® | CBCï¼ˆå«åˆ†é¡ï¼‰ã€è…åŠŸèƒ½ï¼ˆè‚Œé…¸é…æ¸…é™¤ç‡ï¼‰ã€é›»è§£è³ª |
| è™•ç½®é˜²è­· | éœ€ä¾ç´°èƒæ¯’æ€§è—¥ç‰©è™•ç½®è¦ç¯„æ“ä½œ |

## å®‰å…¨æ€§è€ƒé‡

**é‡è¦è­¦èª**ï¼š
- Carboplatin ä¸»è¦ç¶“è…è‡Ÿæ’æ³„ï¼Œè…åŠŸèƒ½ä¸å…¨æ‚£è€…éœ€èª¿æ•´åŠ‘é‡
- éª¨é«“æŠ‘åˆ¶ç‚ºä¸»è¦æ¯’æ€§ï¼Œéœ€å®šæœŸç›£æ¸¬è¡€çƒè¨ˆæ•¸
- å¯èƒ½å¼•èµ·éæ•åæ‡‰ï¼Œå°¤å…¶æ˜¯å¤šæ¬¡ä½¿ç”¨å¾Œ

**è—¥ç‰©äº¤äº’ä½œç”¨**ï¼š
- èˆ‡å…¶ä»–éª¨é«“æŠ‘åˆ¶è—¥ç‰©ä½µç”¨å¯èƒ½å¢åŠ è¡€æ¶²æ¯’æ€§
- èˆ‡è…æ¯’æ€§è—¥ç‰©ï¼ˆå¦‚ aminoglycoside æŠ—ç”Ÿç´ ï¼‰ä½µç”¨éœ€è¬¹æ…
- é¿å…èˆ‡æ´»æ€§ç–«è‹—åŒæ™‚ä½¿ç”¨

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

**è‘¡è„æŸš** ğŸŸ¢ Minor
- å½±éŸ¿ï¼šè‘¡è„æŸšå°é‰‘é¡åŒ–ç™‚è—¥å½±éŸ¿è¼ƒå°
- å»ºè­°ï¼šç„¡éœ€ç‰¹åˆ¥é™åˆ¶



### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Peripheral Nervous System Diseases** ğŸ”´ Major
- Mild peripheral neuropathy has been noted during carboplatin therapy and is characterized most frequently by paresthesias.  Patients older than 65 years and/or previously treated with cisplatin appear to be at increased risk for peripheral neuropathy...

**Infections** ğŸŸ¢ Minor
- Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All pat...

**Hemorrhagic Disorders** ğŸŸ¢ Minor
- The use of carboplatin is contraindicated in patients with significant bleeding.  Carboplatin causes severe myelosuppression and dose-dependent thrombocytopenia.  Patients should be instructed to immediately report any signs or symptoms suggesting bl...

**Bone Marrow Failure Disorders** ğŸŸ¢ Minor
- The use of carboplatin is contraindicated in patients with severe myelosuppression.  Carboplatin induces dose-dependent leukopenia, thrombocytopenia, and anemia, which is cumulative and also dose limiting.  Therapy with carboplatin should be administ...

**è…è‡Ÿç–¾ç—… (Kidney Diseases)** ğŸŸ¢ Minor
- Carboplatin is primarily eliminated by the kidney.  Total body and renal clearance of carboplatin are reduced in patients with a creatinine clearance < 60 mL/min.  Patients with impaired renal function are at increased risk for toxicity, particularly...

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šProceed with Guardrails**

**ç†ç”±ï¼š**
Carboplatin åœ¨ä¹³è…ºç™Œæ²»ç™‚ä¸­å·²æœ‰å¤§é‡è‡¨åºŠè©¦é©—è­‰æ“šæ”¯æŒï¼Œå°¤å…¶åœ¨ä¸‰é™°æ€§ä¹³è…ºç™Œå’Œ BRCA çªè®Šç›¸é—œä¹³è…ºç™Œä¸­é¡¯ç¤ºè‰¯å¥½ç™‚æ•ˆã€‚å¤šé … Phase 2/3 è©¦é©—å·²å®Œæˆæˆ–æ­£åœ¨é€²è¡Œä¸­ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- å¯†åˆ‡ç›£æ¸¬éª¨é«“æŠ‘åˆ¶å’Œè…åŠŸèƒ½
- é‡å°ç‰¹å®šåˆ†å­äºå‹ï¼ˆå¦‚ BRCA çªè®Šã€ä¸‰é™°æ€§ï¼‰çš„å€‹é«”åŒ–ç”¨è—¥ç­–ç•¥
- èˆ‡è…«ç˜¤ç§‘åœ˜éšŠå¯†åˆ‡åˆä½œï¼Œåˆ¶å®šé©ç•¶çš„ä½µç”¨æ–¹æ¡ˆ


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Oteracil]({{ "/drugs/oteracil/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Gemcitabine]({{ "/drugs/gemcitabine/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Dronedarone]({{ "/drugs/dronedarone/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Hydroxyprogesterone Caproate]({{ "/drugs/hydroxyprogesterone_caproate/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Vonoprazan]({{ "/drugs/vonoprazan/" | relative_url }}) - è­‰æ“šç­‰ç´š L2

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Carboplatinè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/carboplatin/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_carboplatin,
  title = {Carboplatinè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/carboplatin/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
